ROTIGAPTIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H39N7O9
Molecular Weight	617.6508
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](NC(=O)CNC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H]2CCCN2C(=O)[C@@H](CC3=CC=C(O)C=C3)NC(C)=O)C(=O)NCC(N)=O

InChI

InChIKey=GFJRASPBQLDRRY-TWTQBQJDSA-N

InChI=1S/C28H39N7O9/c1-15(25(41)30-12-23(29)39)32-24(40)13-31-26(42)22-11-19(38)14-35(22)28(44)21-4-3-9-34(21)27(43)20(33-16(2)36)10-17-5-7-18(37)8-6-17/h5-8,15,19-22,37-38H,3-4,9-14H2,1-2H3,(H2,29,39)(H,30,41)(H,31,42)(H,32,40)(H,33,36)/t15-,19+,20-,21-,22-/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16344331 | https://clinicaltrials.gov/ct2/show/NCT00137332 |

Rotigaptide (previously known as ZP123) originally was developed by Zealand Pharma as a stable antiarrhythmic peptide analog, which maintains gap junction intercellular communication. Then this drug was licensed to Wyeth Pharmaceuticals where it studied in phase II clinical trials in patients with coronary artery disease and with atrial fibrillation. However, these researches have been discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
ZP123 increases gap junctional conductance and prevents reentrant ventricular tachycardia during myocardial ischemia in open chest dogs.	2003 May	12776869
The antiarrhythmic peptide analog rotigaptide (ZP123) stimulates gap junction intercellular communication in human osteoblasts and prevents decrease in femoral trabecular bone strength in ovariectomized rats.	2005 Nov	16109789

Name

Type

Language

ROTIGAPTIDE

Official Name

English

ROTIGAPTIDE [USAN]

Common Name

English

ZP-123 (ZEALAND)

Code

English

ZP-123

Code

English

rotigaptide [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47793